DICE Therapeutics, Inc. (DICE): Price and Financial Metrics

DICE Therapeutics, Inc. (DICE): $47.55

0.03 (+0.06%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

Add DICE to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#364 of 387

in industry

DICE Price/Volume Stats

Current price $47.55 52-week high $47.90
Prev. close $47.52 52-week low $15.08
Day low $47.46 Volume 4,332,900
Day high $47.83 Avg. volume 1,028,719
50-day MA $42.55 Dividend yield N/A
200-day MA $34.31 Market Cap 2.27B

DICE Stock Price Chart Interactive Chart >


DICE Therapeutics, Inc. (DICE) Company Bio


DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is S011806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2013 and is headquartered in South San Francisco, California.


DICE Latest News Stream


Event/Time News Detail
Loading, please wait...

DICE Latest Social Stream


Loading social stream, please wait...

View Full DICE Social Stream

Latest DICE News From Around the Web

Below are the latest news stories about DICE THERAPEUTICS INC that investors may wish to consider to help them evaluate DICE as an investment opportunity.

Lilly Announces Extension of Tender Offer to Acquire DICE

Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of DICE Therapeutics, Inc. (NASDAQ: DICE), for a purchase price of $48 per share in cash, without interest and less any applicable tax withholding.

Yahoo | July 25, 2023

Cardlytics and Motorcar Parts of America Stock See Action From Activist Investors

CAS Investment switched to an activist stance in digital-marketing company Cardlytics. Bison Capital increased its investment in retailer Motorcar Parts.

Yahoo | June 30, 2023

Mergers Are Down, but These 2 Sectors Are Booming

Total deal value worldwide is about $1.22 trillion year to date, according to data from London Stock Exchange Group.

Yahoo | June 27, 2023

4 big deal reports: IBM to buy out Apptio for $5B, per media reports

Here is your Pro Recap of four head-turning deal dispatches you may have missed this week: IBM and Apptio merger rumors, Eli Lilly acquires Dice Therapeutics, Amazon's iRobot acquisition faces EU antitrust investigation, and Stratasys determines 3D Systems' offer not a 'Superior Proposal' to Desktop Metal agreement. InvestingPro subscribers got this news first.

Yahoo | June 24, 2023

Why Dice Therapeutics Stock Bolted Higher This Week

The big gain came after the company announced a $2.4 billion buyout agreement with industry heavyweight Eli Lilly (NYSE: LLY). Through this buyout, Lilly will add the experimental immunology medicines DC-806 and DC-853 to its pipeline. DC-806 is presently in midstage testing as a treatment for psoriasis.

Yahoo | June 22, 2023

Read More 'DICE' Stories Here

DICE Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 72.53%
3-year N/A
5-year N/A
YTD N/A
2023 0.00%
2022 23.27%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!